sinc
first
describ
skou
year
ago
na
katpas
extens
studi
novel
concept
structur
physiolog
biolog
role
continu
appear
classic
role
na
katpas
maintain
electrolyt
homeostasi
cell
pump
cation
cell
use
energi
obtain
hydrolysi
adenosin
triphosph
atp
howev
na
katpas
also
key
scaffold
protein
abl
interact
signal
protein
protein
kinas
c
pkc
phosphoinositid
also
work
classic
receptor
bind
cardiac
glycosid
induc
activ
tyrosin
kinas
src
downstream
signal
cascad
independ
chang
intracellular
ion
virus
intracellular
parasit
whose
life
cycl
depend
hijack
cellular
function
like
protein
synthesi
intracellular
transport
molecul
promot
replic
spread
infect
begin
attach
viral
particl
surfaceexpos
cellular
molecul
entri
cell
endocytosi
viral
compon
intracellular
environ
genom
transcrib
viral
protein
synthes
use
host
cell
translat
machineri
new
viral
particl
transport
surfac
releas
infect
cell
virus
frequent
caus
agent
human
infecti
diseas
cancer
treatment
often
challeng
resist
antivir
drug
report
mani
import
pathogen
influenza
hepat
b
herp
simplex
viru
target
host
cell
compon
na
katpas
promis
antivir
strategi
order
minim
resist
antivir
drug
shown
effect
broad
spectrum
viral
speci
review
analyz
effect
viral
infect
na
katpas
function
effect
na
katpas
ligand
cardiac
glycosid
viral
biolog
also
review
mechan
drug
impair
replic
differ
type
virus
tabl
na
katpas
function
directli
affect
dna
rna
virus
human
parvoviru
dna
viru
tropism
erythroid
progenitor
cell
caus
erythema
infectiosum
fifth
diseas
children
patholog
condit
arthropathi
pure
red
blood
cell
aplasia
express
human
parvoviru
capsid
protein
decreas
na
katpas
activ
xenopu
oocyt
partial
due
phospholipas
activ
depend
format
lysophosphatidylcholin
addit
chiu
et
al
found
recombin
also
decreas
na
katpas
express
cell
infect
rna
virus
also
affect
express
activ
na
katpas
na
katpas
downregul
alveolar
epitheli
cell
infect
influenza
affect
alveolar
fluid
clearanc
addit
influenza
viru
infect
induc
decreas
express
na
katpas
plasma
membran
alveolar
epitheli
cell
paracrin
factor
releas
infect
cell
na
katpas
activ
also
decreas
sindbi
viru
enteroviru
coxsacki
b
infect
caus
import
chang
intracellular
concentr
potassium
sodium
consequ
membran
potenti
interestingli
enteroviru
agent
hand
footandmouth
diseas
hfmd
pediatr
popul
interact
subunit
na
katpas
caus
increas
express
cardiac
glycosid
famili
steroid
compound
commonli
use
treatment
cardiac
diseas
glycosid
inhibit
na
katpas
pump
function
result
chang
intracellular
concentr
sodium
potassium
calcium
also
trigger
signal
transduct
pathway
low
concentr
well
understood
whether
action
cardiac
glycosid
viral
replic
due
chang
ion
homeostasi
activ
intracellular
signal
pathway
howev
compound
effect
divers
virus
infer
mechan
affect
host
process
crucial
viral
replic
cardiac
glycosid
inhibit
cytomegaloviru
cmv
replic
herpesviru
caus
import
human
diseas
nanomolar
concentr
addit
effect
combin
antivir
drug
cmv
ganciclovir
recent
public
cohen
et
al
panel
cardiac
glycosid
use
studi
efficaci
cmv
human
lung
fibroblast
found
inhibitori
activ
cmv
replic
due
decreas
viral
protein
translat
antivir
potenc
depend
structur
cardiac
glycosid
specif
interact
na
katpas
cardiac
glycosid
also
effect
dna
virus
herp
simplex
viru
hsv
inhibit
express
viral
gene
antivir
action
correl
potenc
na
katpas
addit
su
et
al
report
digitoxin
inhibit
hsv
replic
effect
concentr
classic
anti
hsv
drug
acyclovir
ganciclovir
higher
digitoxin
impair
hsv
viral
life
cycl
two
differ
step
viral
dna
synthesi
viral
releas
form
host
cell
author
also
show
other
cardiac
glycosid
digoxin
ouabain
gstrophanthin
compar
antihsv
activ
final
adenovirus
common
human
pathogen
also
suscept
cardiac
glycosid
digitoxin
digoxin
abl
impair
adenoviru
genom
replic
alter
host
prerna
splice
machineri
divers
rna
virus
vulner
cardiac
glycosid
treatment
chikungunya
viru
agent
human
epidem
mosquitoborn
diseas
suscept
treatment
cardiac
glycosid
ashbrook
et
al
screen
librari
small
molecul
capac
modul
chikungunya
viru
infect
human
osteosarcoma
cell
found
digoxin
antivir
activ
chikungunya
alphavirus
includ
river
viru
sindbi
viru
vesicular
stomat
viru
impair
viral
cycl
post
entri
step
via
inhibit
na
katpas
moreov
rna
virus
affect
na
katpas
inhibit
coronavirus
caus
intestin
respiratori
diseas
respons
middleeast
respiratori
syndrom
merscov
epidem
sever
acut
respiratori
syndrom
sarscov
human
repress
na
katpas
silenc
inhibit
low
dose
cardiac
glycosid
effect
caus
impair
viru
entri
earli
stage
importantli
cardiac
glycosid
antivir
effect
reliev
inhibit
src
pathway
transmiss
gastroenter
coronaviru
tgev
also
suscept
ouabain
digitoxin
respiratori
syncyti
viru
rsv
common
caus
season
respiratori
diseas
children
lead
sever
respiratori
failur
contribut
hospit
mortal
pediatr
popul
specif
antivir
treatment
vaccin
yet
avail
ouabain
concentr
nm
inhibit
rsv
replic
vitro
model
also
ebola
viru
ev
trigger
sever
hemorrhag
fever
human
high
mortal
rate
inhibit
cardiac
glycosid
na
katpas
identifi
proteom
analysi
ev
interact
host
cell
protein
nanomolar
concentr
ouabain
abl
impair
viral
replic
decreas
level
viral
rna
addit
find
confirm
screen
compound
activ
ev
influenza
infecti
diseas
caus
variou
type
influenza
viru
character
highli
contagi
acut
respiratori
syndrom
carri
signific
morbid
mortal
worldwid
mani
influenza
strain
develop
pharmacolog
resist
avail
antivir
drug
develop
new
antiinfluenza
treatment
great
interest
recent
year
pharmacolog
screen
studi
highlight
potenti
efficaci
cardiac
glycosid
antiinfluenza
drug
highthroughput
screen
made
hoffmann
et
al
found
nanomolar
dose
na
katpas
inhibitor
ouabain
lanatosid
c
exert
inhibit
influenza
viru
replic
vitro
moreov
subunit
na
katpas
interact
influenza
protein
knockdown
decreas
influenza
viru
replic
also
observ
inhibit
na
katpas
cardiac
glycosid
decreas
influenza
viru
replic
inhibit
host
cell
translat
machineri
via
decreas
intracellular
potassium
consist
author
shown
ouabain
affect
bud
rate
influenza
viru
mdck
madindarbi
canin
kidney
infect
cell
interestingli
human
immunodefici
viru
hiv
also
suscept
cardiac
glycosid
treatment
hiv
infect
worldwid
spread
infecti
diseas
affect
million
peopl
around
globe
lead
acquir
immunodefici
syndrom
aid
treat
increas
risk
opportunist
infect
type
cancer
screen
studi
laird
et
al
differ
member
cardiac
glycosid
famili
shown
activ
moreov
wong
et
al
demonstr
digoxin
inhibit
replic
clinic
strain
impair
splice
mechan
viral
rna
consequ
diminish
structur
protein
synthesi
viru
recent
work
publish
group
report
low
concentr
cardiac
glycosid
inhibit
gene
express
modul
mitogenactiv
protein
kinasesextracellular
signalregul
kinas
signal
via
interact
na
katpas
independ
alter
intracellular
calcium
although
strong
vitro
evid
antivir
activ
na
katpas
modul
littl
known
intracellular
mechan
lead
effect
seem
clear
either
activ
signal
cascad
alter
concentr
intracellular
ion
bind
cardiac
glycosid
na
katpas
determin
environ
unfavor
viral
replic
main
antivir
mechan
suggest
dna
rna
virus
decreas
transcript
viral
gene
impair
synthesi
viral
protein
interf
host
translat
machineri
instanc
replic
hsv
affect
pretreat
high
dose
digitoxin
via
reduct
genom
dna
transcript
h
post
infect
interestingli
digitoxin
also
inhibit
viral
releas
hsv
therebi
act
two
differ
stage
viral
cycl
concordantli
kapoor
et
al
show
anoth
herpesviru
human
cmv
also
suscept
cardiac
glycosid
via
inhibit
viral
dna
replic
describ
reduc
level
nuclear
factor
h
postinfect
decreas
express
intermediateearli
viral
protein
author
hypothes
inhibitori
mechan
might
mediat
via
interact
na
k
atpas
ion
channel
like
voltageg
k
channel
herg
whose
express
induc
cmv
infect
downregul
cardiac
glycosid
treatment
cmv
protein
synthesi
also
shown
decreas
cell
treat
cardiac
glycosid
convallatoxin
mechan
propos
decreas
transport
essenti
amino
acid
methionin
without
affect
viral
mrna
accumul
howev
author
studi
mechan
link
na
katpas
modul
alter
amino
acid
transport
wong
et
al
studi
mechan
cardiac
glycosid
activ
hiv
author
observ
digoxin
inhibit
hiv
replic
impair
altern
splice
viral
premrna
need
synthesi
hiv
protein
therefor
reduc
viral
gene
express
mechan
confirm
use
clinic
strain
human
cell
addit
author
observ
digoxin
select
inhibit
key
regulatori
protein
rev
lead
impair
export
revdepend
mrna
produc
viral
structur
protein
although
mechan
cardiac
glycosid
interfer
host
altern
splice
machineri
remain
unclear
propos
digoxininduc
alter
signal
cascad
affect
activ
factor
known
regul
rna
splice
factor
includ
kinas
protein
sr
shown
modul
digoxin
moreov
recent
public
author
report
cardiac
glycosid
famili
cardenolid
vertebratederiv
bufadenolid
plantderiv
antihiv
activ
vitro
ex
vivo
hivinfect
cell
human
inhibitori
effect
nanomolar
rang
importantli
inhibit
gene
express
drug
independ
chang
mitogenactiv
protein
kinas
mapk
src
activ
cardiac
glycosid
trigger
classic
mapk
extracellular
signalregul
kinas
erk
signal
rafmek
cascad
observ
inhibit
gene
express
highlight
import
intracellular
signal
trigger
cardiac
glycosid
bind
potenti
therapeut
strategi
hiv
similarli
grosso
et
al
observ
adenoviru
also
depend
host
rna
splice
machineri
suscept
cardiac
glycosid
treatment
author
found
digoxin
digitoxin
affect
synthesi
viral
protein
reduc
express
late
viral
protein
mrna
alter
rna
splice
favor
product
rna
isoform
earli
infect
partial
block
transit
rna
isoform
late
stage
viru
replic
src
signal
also
report
involv
inhibit
coronaviru
vesicular
stomat
viru
infect
inhibit
viru
rescu
inhibitor
src
cardiac
glycosid
propos
affect
entri
stage
viru
interf
endocytosi
nonelucid
pathway
interestingli
influenza
viru
infect
affect
mechan
inde
result
show
influenza
viru
impair
ouabain
nanomolar
concentr
inhibit
translat
viral
protein
decreas
concentr
intracellular
potassium
na
katpas
ubiquit
transmembran
protein
pump
ion
cell
also
play
import
role
intracellular
signal
process
due
effect
na
katpas
use
cardiac
glycosid
antivir
drug
promis
strong
inhibitori
effect
drug
occur
differ
level
life
cycl
differ
viru
speci
howev
public
profoundli
studi
mechan
action
cardiac
glycosid
antivir
drug
main
find
correl
either
impair
viral
genom
replic
decreas
viral
mrna
protein
synthesi
suggest
drug
target
host
process
essenti
virus
accomplish
success
replic
cycl
mechan
explor
order
develop
novel
antivir
treatment
two
import
advantag
low
risk
resist
broad
spectrum
action
